Use of miltefosine in a patient with mucosal leishmaniasis and HIV-coinfection: A challenge in long-term management

Giacomo Zanelli, Barbara Rossetti, Roberta Gagliardini, Lorenzo Paglicci, Giacinta Tordini, Clelia Miracco, Sara Aversa, Lorenzo Zammarchi, Trentina Di Muccio, Marina Gramiccia, Francesca Montagnani

Research output: Contribution to journalArticle

Abstract

The management of mucosal leishmaniasis in immunocompromised patients is not standardized and limited data are available on the use of miltefosine for treatment and secondary prophylaxis. We describe a case of mucosal leishmaniasis in an HIV-coinfected patient treated with miltefosine due to a severe allergic reaction to liposomal amphotericin B.

Original languageEnglish
Pages (from-to)452-455
Number of pages4
JournalInfezioni in Medicina
Volume27
Issue number4
Publication statusPublished - Dec 1 2019

    Fingerprint

Keywords

  • Adverse reaction
  • HIV
  • Liposomal B amphotericin
  • Miltefosine
  • Mucosal leishmaniasis

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Zanelli, G., Rossetti, B., Gagliardini, R., Paglicci, L., Tordini, G., Miracco, C., Aversa, S., Zammarchi, L., Di Muccio, T., Gramiccia, M., & Montagnani, F. (2019). Use of miltefosine in a patient with mucosal leishmaniasis and HIV-coinfection: A challenge in long-term management. Infezioni in Medicina, 27(4), 452-455.